Recent advances in immunotherapy for relapsed or refractory multiple myeloma

doi:10.3760/cma.j.cn371439-20200214-00117

Abstract

Abstract:

Immunotherapy strategies have shown benefits in the treatment of multiple myeloma (MM), however a certain percentage of patients progress to relapsed or refractory MM. In addition to monoclonal antibodies against antigens on tumor cells, the latest immunotherapy strategies include bispecific antibodies, immune checkpoint inhibitors, chimeric antigen receptor modified T cell and Bruton tyrosine kinase inhibitors, which provide more possibilities for immunotherapy of relapsed or refractory MM.

Key words: Multiple myeloma, Antibodies, monoclonal, Immunosuppressive agents, Antibodies drug conjugates

Hou Yuanmei, Li Junpeng. Recent advances in immunotherapy for relapsed or refractory multiple myeloma[J]. Journal of International Oncology, 2020, 47(12): 765-768.

References 28

[1]	Moreau P, San Miguel J, Sonneveld P , et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2017,28Supple 4: iv52-iv61. DOI: 10.1093/annonc/mdx096.
[2]	Muccio VE, Saraci E, Gilestro M, et al. Multiple myeloma: new surface antigens for the characterization of plasma cells in the era of novel agents[J]. Cytometry B Clin Cytom, 2016,9(1):81-90. DOI: 10.1002/cyto.b.21279.
[3]	Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab[J]. Clin Cancer Res, 2017,23(24):7498-7511. DOI: 10.1158/1078-0432.CCR-17-2027.
[4]	Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016,375(8):754-766. DOI: 10.1056/NEJMoa1606038.
[5]	Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: update danalysis of POLLUX[J]. Haematologica, 2018,103(12):2088-2096. DOI: 10.3324/haematol.2018.194282. pmid: 30237262
[6]	Luo XW, Du XQ, Li JL, et al. Treatment options for refractory/relapsed multiple myeloma: an updated evidence synjournal by network meta-analysis[J]. Cancer Manag Res, 2018,10:2817-2823. DOI: 10.2147/CMAR.S166640.
[7]	Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab[J]. Mol Cancer Ther, 2018,17(7):1454-1463. DOI: 10.1158/1535-7163.MCT-17-0998. pmid: 29654064
[8]	Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenali-domide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial[J]. Cancer, 2018,124(20):4032-4043. DOI: 10.1002/cncr.31680.
[9]	Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma[J]. Blood, 2014,123(20):3128-3138. DOI: 10.1182/blood-2013-10-535088. pmid: 24569262
[10]	Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial[J]. Lancet Oncol, 2018,19(12):1641-1653. DOI: 10.1016/S1470-2045(18)30576-X.
[11]	Pahl A, Lutz C, Hechler T, et al. Amanitins and their development as a payload for antibody-drug conjugates[J]. Drug Discov Today Technol, 2018,30:85-89. DOI: 10.1016/j.ddtec.2018.08.005.
[12]	Cohen AD, Garfall AL, Dogan A, et al. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies[J]. Blood Adv, 2019,3(16):2487-2490. DOI: 10.1182/bloodadvances.2019000466.
[13]	Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo[J]. Leukemia, 2017,31(8):1743-1751. DOI: 10.1038/leu.2016.388.
[14]	Seckinger A, Delgado JA, Moser S, et al. Target expression, gene-ration, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment[J]. Cancer Cell, 2017,31(3):396-410. DOI: 10.1016/j.ccell.2017.02.002.
[15]	Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma[J]. Cancer Immunol Res, 2018,6(7):776-787. DOI: 10.1158/2326-6066.CIR-17-0649. doi: 10.1158/2326-6066.CIR-17-0649 pmid: 29769244
[16]	Ramadoss NS, Schulman AD, Choi SH, et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma[J]. J Am Chem Soc, 2015,137(16):5288-5291. DOI: 10.1021/jacs.5b01876.
[17]	Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma[J]. Clin Cancer Res, 2015,21(20):4607-4618. DOI: 10.1158/1078-0432.CCR-15-0200. doi: 10.1158/1078-0432.CCR-15-0200 pmid: 25979485
[18]	Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immuno-therapy for myeloma[J]. J Immunother Cancer, 2015,3(1):2. DOI: 10.1186/s40425-014-0043-z.
[19]	Garfall AL, Stadtmauer EA, Hwang WT, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma[J]. JCI Insight, 2018,3(8):e120505. DOI: 10.1172/jci.insight.120505.
[20]	Lee L, Draper B, Chaplin N, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma[J]. Blood, 2018,131(7):746-758. DOI: 10.1182/blood-2017-05-781351. pmid: 29284597
[21]	Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma[J]. N Engl J Med, 2015,373(11):1040-1047. DOI: 10.1056/NEJMoa1504542. pmid: 26352815
[22]	Chen D, Zou J, Zong Y, et al. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization[J]. Immunopharmacol Immunotoxicol, 2016,38(3):175-183. DOI: 10.3109/08923973.2016.1153110.
[23]	Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease[J]. Histol Histopathol, 2014,29(2):177-189. DOI: 10.14670/HH-29.177. pmid: 24150912
[24]	Fichou N, Gouard S, Maurel C, et al. Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model[J]. Front Med (Lausanne), 2015,2:76. DOI: 10.3389/fmed.2015.00076.
[25]	Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma[J]. Clin Cancer Res, 2018,24(1):106-119. DOI: 10.1158/1078-0432.CCR-17-0344. pmid: 29061640
[26]	Shi Y, Wang G, Muhowski EM, et al. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells[J]. Leukemia, 2019,33(7):1650-1662. DOI: 10.1038/s41375-019-0381-4.
[27]	Natarajan G, Terrazas C, Oghumu S, et al. Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells[J]. OncoImmunology, 2015,5(1):e1057385. DOI: 10.1080/2162402X.2016.1057385. pmid: 26942065
[28]	Ma J, Gong W, Liu S, et al. Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3[J]. Tumour Biol, 2018,40(1):1010428317731369. DOI: 10.1177/1010428317731369. doi: 10.1177/1010428317731369 pmid: 29320977